Anti-Met (c-Met) antibody (ab14570)

Overview

• Product nameAnti-Met (c-Met) antibodySee all Met (c-Met) primary antibodies ...
• Description
  Rabbit polyclonal to Met (c-Met)
• Tested applicationsIP, WB more details
• Species reactivity
  Reacts with: Mouse, Dog
  Predicted to work with: Rat
• Immunogen

  Synthetic peptide: APYPSLLPSQDNIDGEGNT conjugated to Ovalbumin, corresponding to amino acids 1361-1379 of Mouse Met (c-Met). The immunizing sequence has 18 of 19 identical amino acids in rat.

  Run BLAST with Run BLAST with
• Positive controlMouse liver membrane fractions.

Properties

• FormLiquid
• Storage instructionsAdd glycerol to a final volume of 50%, aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.05% Sodium Azide
  Constituents: 30% Glycerol, 0.15M Sodium Chloride, 0.1M Tris-glycine. pH 7.4
• Concentration information loading...
• PurityProtein A purified
• Primary antibody notes Met (c-Met), a high affinity receptor for hepatocyte growth factor (HGF; also known as scatter factor), is a disulfide-linked heterodimer made of 45kD alpha and 145kD beta subunits. The alpha subunit and the amino-terminal region of beta-subunit form the extracellular domain. The remainder of the beta-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met (c-Met) with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl and PI3 kinase and is critical for all of its known biological functions. Phosphorylation of Tyr1234/1235 in the Met kinase domain is critical to kinase activation. Phosphorylation of Tyr1349 in the Met (c-Met) cytoplasmic domain provides a direct binding site for Gab1. Altered Met (c-Met) levels and/or tyrosine kinase activities were found in different tumors, especially in renal, colon and breast cancers. Thus, Met (c-Met) is an attractive therapeutic target and cancer diagnostic.
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Cancer
  • Oncoproteins/suppressors
  • Oncoproteins
  • Growth factor receptors

  • Signal Transduction
  • Protein Phosphorylation
  • Tyrosine Kinases
  • Receptor Tyrosine Kinases

  • Epigenetics and Nuclear Signaling
  • Transcription
  • Cancer susceptibility
  • Proto-oncogenes

Applications

Target

• FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
• Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
  Note=Defects in MET may be associated with gastric cancer.
  Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
  Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
  Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
  Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
• Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
  Contains 3 IPT/TIG domains.
  Contains 1 protein kinase domain.
  Contains 1 Sema domain.
• DomainThe kinase domain is involved in SPSB1 binding.
• Post-translational
  modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
• Cellular localizationMembrane.

Target information above from: UniProt accession P08581 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 403438 Dog
  • Entrez Gene: 17295 Mouse
  • Entrez Gene: 24553 Rat
  • SwissProt: Q75ZY9 Dog
  • SwissProt: P16056 Mouse
  • SwissProt: P97523 Rat
  • Unigene: 86844 Mouse
  • Unigene: 10617 Rat

• Alternative names
  AUTS9 antibodyc met antibodycmet antibody

  D249 antibodyHepatocyte growth factor receptor antibodyHepatocyte growth factor receptor Precursor antibodyHGF antibodyHGF receptor antibodyHGF SF receptor antibodyHGF/SF receptor antibodyHGFR antibodyMET antibodyMet proto oncogene tyrosine kinase antibodyMet proto-oncogene (hepatocyte growth factor receptor) antibodyMet proto-oncogene antibodyMet protooncogene antibodyMET_HUMAN antibodyOncogene MET antibodyPar4 antibodyProto-oncogene c-Met antibodyRCCP2 antibodyRenal cell carcinoma papillary 2 gene antibodyScatter factor receptor antibodySF receptor antibodyTyrosine-protein kinase Met antibody

  see all